IJCS | Volume 33, Nº2, March / April 2020

It is essential that patients with resistant hypertension and possible associated clinical conditions be properly identified. For an effective treatment, there must be awareness and interactionof patientswith the health team, selection of pharmacological and nonpharmacological treatment, and good treatment adherence, aiming at blood pressure control and reduction of morbidity and mortality of these high-risk patients. 1. Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brand o AA, Neves MFT, et al., Sociedade Brasileira de Cardiologia. VII Diretriz 
Brasileira de Hipertens o Arterial. Arq Bras Cardiol 2016; 107(3Supl.3):1-83. 2. Whelton PK, Carey RM, AronowWS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, andManagement of High Blood Pressure inAdults:AReport of theAmerican College of Cardiology/AmericanHeartAssociation Task Force on Clinical Practice Guidelines.. Hypertension. 2018;71(6):e13-e115.  3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, et al. 2018 ESC/ESHGuidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 ;36(10):1953-2041. 4. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov;72(5):e53-e90. 5. Alessi A,   Brand o AA,   Coca A,   Cordeiro AC,   Nogueira AR, Magalh es DF, et al. First Brazilian position on resistant hypertension. Arq Bras Cardiol.  2012;99(1):576-85. 6. Araujo LBS, Aras-Junior R. Association between TherapeuticAdherence and the Profile of Patients with Resistant Hypertension. Int J Cardiovasc Sci. 2020; 33(2):121-130. 7. Krieger EM,   Drager LF,   Giorgi DMA,   Pereira AC,   Barreto-Filho JAS,   Nogueira AR,  et al. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension.  2018 Apr;71(4):681-90. 8. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): arandomised,double-blind,crossovertrial.Lancet.2015;386(10008):2059-68. 9. Egan BM, Zhao Y,Axon RN, Brzezinski WA, FerdinandKC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.Circulation. 2011; 124:1046–1058. doi: 10.1161/ CIRCULATIONAHA.111.030189. 10. Lotufo PA, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Hypertens (Greenwich). 2015;17(9):74-80. 11. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension.  2019 Feb;73(2):424-31. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 120 Malachias The challenge of resistant hypertension Int J Cardiovasc Sci. 2020; 33(2):119-120 Editorial